JANX Janux Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1817713 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY132.9%
TTM net income YoY2.0%
TTM EPS YoY4.8%
Revenue 3-yr CAGR40.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-599.3%
Net margin-428.7%
FCF margin-232.6%
EBITDA margin-591.3%
Returns
ROE-10.6%
ROA-9.9%
ROIC (approx.)-12.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets7.3%
Debt / equity0.00x
Current ratio17.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.29M | $10.27M | $3.73M | $0 | $10.00M | $0 | $0 | $0 |
| R&D expense | $30.57M | $30.99M | $26.81M | $31.55M | $34.63M | $34.66M | $25.05M | $20.81M |
| SG&A expense | $9.98M | $10.96M | $11.13M | $10.85M | $10.62M | $10.45M | $9.84M | $8.22M |
| Operating income | -$31.26M | -$31.69M | -$34.21M | -$42.40M | -$35.25M | -$45.12M | -$34.90M | -$29.02M |
| Net income | -$21.57M | -$21.97M | -$24.36M | -$31.95M | -$24.31M | -$33.86M | -$23.51M | -$20.22M |
| EBITDA | -$30.80M | -$31.23M | -$33.74M | -$41.93M | -$34.75M | -$44.58M | -$34.38M | -$28.51M |
| EPS (basic) | -0.34 | -0.35 | -0.39 | — | -0.39 | -0.55 | -0.38 | — |
| EPS (diluted) | -0.34 | -0.35 | -0.39 | — | -0.39 | -0.55 | -0.38 | — |
| Weighted avg. shares (diluted) | 63.09M | 62.94M | 62.67M | — | 62.02M | 61.90M | 61.79M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.82M | $27.77M | $51.83M | $52.33M | $48.39M | $52.45M | $73.74M | $430.61M |
| Short-term investments | $903.90M | $943.14M | $904.56M | $914.23M | $940.60M | $943.57M | $940.40M | $594.57M |
| Receivables | $411,000 | $149,000 | $35.00M | $0 | — | — | — | — |
| Current assets | $959.38M | $983.34M | $1.00B | $975.89M | $998.09M | $1.01B | $1.02B | $1.03B |
| PP&E, net | $2.79M | $3.26M | $3.55M | $3.85M | $4.31M | $4.69M | $4.95M | $4.86M |
| Total assets | $983.65M | $1.01B | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B | $1.06B |
| Current liabilities | $54.25M | $60.15M | $58.91M | $25.00M | $27.83M | $21.38M | $17.50M | $17.46M |
| Total liabilities | $72.04M | $79.67M | $86.69M | $44.74M | $48.21M | $41.70M | $38.30M | $38.73M |
| Shareholders' equity | $911.61M | $927.98M | $941.53M | $956.82M | $976.55M | $990.52M | $1.01B | $1.02B |
| Shares outstanding | 61.17M | 61.08M | 60.87M | 60.38M | 60.12M | 59.30M | 59.17M | 59.06M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.18M | $12.48M | -$12.34M | -$28.54M | -$12.86M | -$23.81M | -$17.02M | -$16.73M |
| Capital expenditure | $2,000 | $202,000 | $273,000 | $106,000 | $93,000 | $473,000 | $371,000 | $42,000 |
| Free cash flow | -$25.18M | $12.28M | -$12.61M | -$28.65M | -$12.95M | -$24.29M | -$17.39M | -$16.77M |
| Investing cash flow | $38.38M | -$38.78M | $8.29M | $29.54M | $8.31M | $1.56M | -$340.39M | $33.93M |
| Financing cash flow | $852,000 | $2.24M | $3.54M | $2.94M | $493,000 | $954,000 | $554,000 | $386.65M |
| Depreciation & amortization | $458,000 | $463,000 | $469,000 | $468,000 | $501,000 | $541,000 | $519,000 | $512,000 |
| Stock-based compensation | $8.54M | $9.06M | $9.27M | $9.52M | $9.04M | $10.96M | $10.70M | $6.25M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.